[197 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.
Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.
Albumin is a major plasma protein critical in regulating blood volume and transporting various substances, including hormones, drugs, and nutrients. It primarily treats hypovolemia (low blood volume), hypoalbuminemia (low albumin levels), and severe burns. Coagulation factor concentrates are essential for treating bleeding disorders such as hemophilia A & B and von Willebrand disease and replace missing or deficient clotting factors, preventing excessive bleeding and promoting proper wound healing. Immunoglobulins are antibodies that play a crucial role in the body's immune response by neutralizing pathogens such as bacteria and viruses and are used to treat primary immunodeficiency diseases, inflammatory and autoimmune disorders, and certain types of cancer. Protease inhibitors are essential for managing hereditary angioedema (HAE), a periodic genetic condition characterized by recurrent episodes of severe swelling in various body parts. These inhibitors block the action of proteases responsible for inflammation and vascular permeability during hereditary angioedema (HAE) attacks.
In the critical care setting, plasma fractionation products are vital for treating life-threatening conditions such as sepsis, burns, and trauma. Plasma fractionation has significant applications in hemato-oncology for managing blood-related cancers and supporting chemotherapy treatments. Hematology involves the prevention, diagnosis, and treatment of blood diseases such as hemophilia or von Willebrand disease (VWD). Plasma fractionation products including IVIG are increasingly used in treating neurological conditions, including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis. In pulmonology, plasma fractionation helps in managing respiratory diseases such as alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). Plasma fractionation is utilized in rheumatology primarily through the use of IVIG to manage autoimmune and inflammatory disorders.
Academic & research institutes are engaged in basic research to advance the understanding of plasma proteins and their therapeutic potential. The key needs for this segment include high-purity plasma fractions for protein characterization studies, advanced fractionation techniques that can lead to discoveries, and access to reliable sources of raw material. Clinical research laboratories are essential for testing and validating plasma fractionation processes and products. They conduct trials to ensure the safety and efficacy of plasma-derived products, assess their impact on patients, and gather data to support regulatory approval. These laboratories are involved in both pre-clinical and clinical stages of product development.
The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.
The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
Grifols, a producer of plasma-derived medicines, has partnered with Egypt's National Service Projects Organization (NSPO) to inaugurate their first plasma-derived medicines. These medicines are manufactured using donations from Egypt, ensuring a reliable and sustainable source. The shipment includes vital plasma therapies such as albumin, which is utilized in major surgeries, trauma treatment, and severe burn cases. Additionally, immunoglobulins (Ig) are included for immunodeficiencies, along with blood-clotting factors to manage bleeding disorders. [Published On: 2023-06-07]
CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
CSL, a biotechnology company, recently celebrated the inauguration of its state-of-the-art plasma fractionation facility in Marburg, Germany. This monumental project, with a budget of USD 470 million, spanned five years and has quadrupled the company's manufacturing capacity for producing life-saving medicines derived from donated human plasma. The new facility, leveraging optimized process flows, cutting-edge technologies, and advanced automation, has significantly enhanced operational efficiency. [Published On: 2023-03-24]
Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
Takeda is making a significant investment of approximately 100 billion yen to construct a state-of-the-art manufacturing facility in Osaka, Japan. This facility is expected to be the largest and specialized in the production of plasma-derived therapies in the country. The investment aligns with Takeda's capital allocation policy, which aims to create value and establish a world-class end-to-end manufacturing facility for PDTs at its Juso, Osaka plant. [Published On: 2023-03-23]
The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.
This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Albumin
- Coagulation Factor Concentrates
- Factor IX
- Factor VIII
- Factor XIII
- Fibrinogen Concentrates
- Prothrombin Complex Concentrate
- Von Willebrand Factor
- Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Protease Inhibitors
- Application
- Critical Care
- Hemato-Oncology
- Hematology
- Neurology
- Pulmonology
- Rheumatology
- End-User
- Academic & Research Institutes
- Clinical Research Laboratories
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Plasma Fractionation Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?
- What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?
- What is the market share of the leading vendors in the Plasma Fractionation Market?
- Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Plasma Fractionation Market, by Product
- Plasma Fractionation Market, by Application
- Plasma Fractionation Market, by End-User
- Americas Plasma Fractionation Market
- Asia-Pacific Plasma Fractionation Market
- Europe, Middle East & Africa Plasma Fractionation Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 476]
- List of Companies Mentioned [Total: 26]
Benefits of Plasma Fractionation:
Plasma is the fluid part of the blood that carries vital proteins and other nutrients throughout the body. Plasma fractionation separates plasma into different fractions, allowing the extraction of useful constituents such as albumin, immunoglobulin, and clotting factors. These fractions can be used to make medications for a range of medical conditions, such as immune deficiencies, hemophilia, and viral infections. The extracted proteins and other blood components are crucial in managing bleeding disorders, preventing infections, and fighting autoimmune diseases.
Plasma Fractionation Process:
The process of plasma fractionation is complex and involves several steps. The first step is to collect blood from donors at a blood donation center or hospital. Next, the blood is collected in a blood bank and tested for infectious agents such as Hepatitis B, C, and HIV. After screening, the plasma is separated from the other blood cells and subjected to a process that breaks it down into its components. The extracted proteins undergo rigorous quality testing to ensure their safety and efficacy. They are then packaged in vials or syringes and shipped to healthcare facilities worldwide.
Impact on the Elderly:
Aging causes several physiological changes that make elderly people more vulnerable to infections, chronic diseases, and blood clotting disorders. The plasma-derived products help in managing these conditions, and they are widely prescribed to elderly patients.
The Future of Plasma Fractionation:
Research in plasma fractionation has shown a promising future for the industry. The development of new technologies, such as nucleic acid-based testing, has improved blood safety and reduced the risk of infectious transmission. The industry is also looking towards the development of new products such as anti-cancer immunotherapies and new clotting factors. Advances in technology and distribution channels have made plasma fractionation drugs more accessible to people around the world.
Plasma fractionation is a vital process that has been improving lives for decades. The significance of plasma-derived products has increased with the rise of the elderly population and the increasing number of blood collection facilities. Plasma-derived products play a key role in the management of diseases like coagulation disorders, immune deficiencies, and infections. The rise of new technologies and research in the field bodes well for the future and will ensure that plasma-derived products continue to improve the quality of life for people around the globe.
- How big is the Plasma Fractionation Market?
- What is the Plasma Fractionation Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?